Company intelligence / Profile preview

Recombia Biosciences

Brisbane, California, United Statesrecombia.com ↗

Ownership: Private
Employees: ~22
Development stage: Commercial

Overview

Recombia Biosciences specializes in high-throughput genome editing and synthetic biology to engineer yeast and bacterial strains for sustainable biomanufacturing. Acquired by Lesaffre in September 2022 after a strategic partnership since 2020, the company leverages proprietary technologies licensed from Stanford University to optimize microbial production of commercial-scale ingredients such as biofuels and nutraceuticals. It operates as part of Lesaffre’s global R&D network but retains its brand identity.

Therapeutic areas: Other
Modalities: Engineered microorganisms (yeast and bacteria)metabolic engineeringsynthetic biology platforms
Industry: Non-Drug Biotech

Partnerships

Strategic partnership then acquisition by Lesaffretechnology licensing from Stanford University

Beyond the preview

Go deeper on Recombia Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recombia Biosciences.

Explore the full profile